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Letters to Editor 
evidence of metastasis. The patient underwent SCRT 
followed by abdominoperineal excision of the rectum 
and anus 19 days later. 
Macroscopically, there was normal mucosa, and seven 
lymph nodes were identified. Histology showed features 
in-keeping with the previous radiotherapy, characterized 
by focal transmural fibrosis and a patchy transmural 
chronic inflammatory infiltrate. No residual neoplasia 
was identified and all lymph nodes showed simple 
reactive changes [Figure 4]. 
Surgery remains the mainstay treatment for rectal 
cancer,[1] although in Europe radiotherapy has been 
used in the neoadjuvant and adjuvant setting for a 
long time, to reduce local recurrence.[4] Short course 
radiotherapy (SCRT) including the Dutch Colorectal 
Cancer Group and the Swedish Rectal Cancer Trial 
demonstrated a reduced risk of local recurrence[2,3] 
and concluded that preoperative SCRT might improve 
survival among patients with resectable rectal cancer.[3]
In both these trials surgery was performed within a week 
of completing radiotherapy. A randomized controlled trial 
from Poland showed no difference in the local recurrence 
rate or survival and toxicity rate when comparing SCRT 
and CRT, which suggests an intensive radiotherapy 
protocol is achieved with SCRT. SCRT achieves similar 
results as those by the prolonged standard CRT.[5] In 
our patient there was a delay of 19 days before radical 
surgery was performed. This could have contributed to 
the complete pathological response. 
There is reasonable literature on chemoradiation 
producing 15-30% complete pathological response[4] 
and this response may be increased with increased time 
delay between neoadjuvant treatment and surgery,[6] but 
this evidence is not conclusive. There is some evidence 
that the subgroup of patients who have favorable tumor 
regression grade and lymph node status may have a 
higher rate of complete response.[7] There is an American 
College of Surgeons Oncology Group (ACOSOG)­
supported prospective trial in progress, using local 
excision following chemoradiation for ultrasound staged 
T2 distal rectal cancer.
[8] In a significant proportion of a 
high-risk patient’s neoadjuvant treatment, either SCRT 
or CRT may result in a complete response, whereby, 
major rectal cancer surgery may be avoided or a local 
excision with minimal morbidity can be performed. 
To test this hypothesis, there is a need for a multi-arm 
randomized controlled trial of early rectal cancer, that is, 
< = T2 with no nodal disease on radiological staging, 
receiving SCRT or CRT with varying periods between 
radiotherapy and radical surgery, to define the optimal 
time period between radiotherapy regimes and surgery 
and to find the subgroup of patients where a major 
resection can be avoided. 
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Breast cancer incidence 
among females in the 
Golestan province, Iran 
Sir, 
Cancer is the third most common cause of death 
in Iran and, annually, 30,000 Iranians die due to
cancer.[1] We evaluated province-specific estimates of 
incidence of breast cancer in females in the Golestan 
province of Iran in 2004. The Golestan province is 
located in the north of Iran, in the south east of the 
Caspian Sea. Data were identified and collected through 
18 Pathology Laboratory centers. Using a structured 
questionnaire, trained personnel conducted in-person 
interviews to collect information on breast cancer. 
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Table 1: Breast cancer incidence among females in the Golestan province in 2004 
Ages 0–4 5–9 10–14 15–19 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84 85+
(years) 
Persons 69,465 84,583 11,2921 12,3107 89,519 67,719 59,689 52,192 35,723 29,885 28,116 21,321 13,615 8240 8614 3909 2923 1818 
Incidence -* - - - - 5.91 10.05 11.50 30.79 43.50 46.24 14.07 7.34 12.14 46.44 51.16 68.42 55.01
rates (per 100,000) 
-*no cancer incidence. 
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Newly diagnosed cases that are detected by histological 
or cytological examinations were sent to the Cancer 
Registry Office of the province and to the registry unit 
in the Health Deputy. Age-specific rates and annual age-
adjusted rates (ASRs) per 100,000 person-years were 
calculated using the direct methods of standardization 
to the world population. Three hundred and forty-eight 
patients with cancer from all sites were seen in 2004, 
with 67 (19.25%) of them having breast cancer. The 
pathologic diagnosis in these cases was infiltrating duct 
carcinoma (68.65%), infiltrating ductular carcinoma 
(4.47%), intra-ductal carcinoma non-infiltrating (4.47%), 
carcinoma (2.98%), lobular carcinoma (2.98%), comdoc 
carcinoma (1.49%), medullary carcinoma (1.49%), 
intra-ductal carcinoma and lobular carcinoma I (1.49%) 
and phyllades tumor, malignant (1.49%). The overall 
incidence was 11.81/100,000 persons. Table 1 shows 
that the highest incidence was in the age range of 
80–84 years and the lowest was in the age range of 
25–29 years. Comparison of the ASR for breast cancer 
among females with those of breast cancer worldwide 
shows that the Golestan province is one of the low-
risk areas. The incidence is lower when compared with 
cancer registry in other countries. The highest incidence 
rates occur in northern and western Europe, northern 
America, Australia and New Zealand and in the southern 
countries of South America, notably Uruguay and 
Argentina. Clear geographical differences in risk are 
apparent within Europe, with elevated rates in northern 
and western Europe, whereas rates in most southern 
and eastern European countries are low to intermediate. 
[2] Incidence is low throughout Africa, Asia and most 
of Central and South America. Rates of more than 100 
per 100,000 are noted in several US states, whereas the 
highest rates are recorded in Montevideo in Uruguay. 
Rates are elevated (50–100 per 100,000) in registries 
in geographically diverse areas of the world, including 
most northern and western European countries, Canada, 
Israel and Argentina. In several Asian populations, 
such as Hong Kong, Singapore (Chinese) and the 
Philippines (Manilla), rates are intermediate (30–50 
per 100,000) as they are in Puerto Rico and Goiania 
(Brazil) in South America and most eastern European 
populations. The lowest rates are seen in several Chinese 
populations, including the Quidong registry (about 
10 per 100,000), whereas observed rates are also low 
(10–30 per 100,000) in eastern African populations in 
Zimbabwe and Uganda, Algiers in North Africa, several 
Southeast Asian registries (Thailand and Vietnam) and 
several registries in India. Koreans living in the USA 
have retained a relatively low breast cancer incidence 
rate (about 28 per 100,000), not dissimilar to that of 
Koreans living in Korea (21 per 100,000 in Seoul).[3] 
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Primary neuroendocrine 
carcinoma of the breast, 
which chemotherapy? 
Sir, 
Primary neuroendocrine carcinomas of the breast 
are extremely uncommon, with only very few cases 
published in English literature. Their best treatment is 
still unknown and various modes of management have 
been employed in treating this disease. 

